Discounted Cash Flow (DCF) Analysis Levered
Yield10 Bioscience, Inc. (YTEN)
$2.76
-0.07 (-2.47%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 0.56 | 0.81 | 0.80 | 0.61 | 0.45 | 0.44 | 0.44 | 0.43 | 0.42 | 0.42 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -8.75 | -8.65 | -8.66 | -9.25 | -11.40 | -6.89 | -6.80 | -6.70 | -6.60 | -6.51 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -0.04 | -0.06 | -0.08 | -0.19 | -0.15 | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -8.80 | -8.71 | -8.74 | -9.44 | -11.56 | -6.97 | -6.87 | -6.77 | -6.68 | -6.58 |
Weighted Average Cost Of Capital
Share price | $ 2.76 |
---|---|
Beta | 1.814 |
Diluted Shares Outstanding | 4.91 |
Cost of Debt | |
Tax Rate | -1.16 |
After-tax Cost of Debt | 5.00% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 12.263 |
Total Debt | 2.65 |
Total Equity | 13.56 |
Total Capital | 16.21 |
Debt Weighting | 16.34 |
Equity Weighting | 83.66 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 0.56 | 0.81 | 0.80 | 0.61 | 0.45 | 0.44 | 0.44 | 0.43 | 0.42 | 0.42 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -8.75 | -8.65 | -8.66 | -9.25 | -11.40 | -6.89 | -6.80 | -6.70 | -6.60 | -6.51 |
Capital Expenditure | -0.04 | -0.06 | -0.08 | -0.19 | -0.15 | -0.08 | -0.08 | -0.08 | -0.08 | -0.08 |
Free Cash Flow | -8.80 | -8.71 | -8.74 | -9.44 | -11.56 | -6.97 | -6.87 | -6.77 | -6.68 | -6.58 |
WACC | ||||||||||
PV LFCF | -6.28 | -5.57 | -4.94 | -4.39 | -3.89 | |||||
SUM PV LFCF | -25.07 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 11.08 |
Free cash flow (t + 1) | -6.71 |
Terminal Value | -73.92 |
Present Value of Terminal Value | -43.71 |
Intrinsic Value
Enterprise Value | -68.78 |
---|---|
Net Debt | 0.29 |
Equity Value | -69.08 |
Shares Outstanding | 4.91 |
Equity Value Per Share | -14.06 |